Supplements

Vitamin K: K1 and K2, food, warfarin, newborn prevention, bone studies, and calcification claims

6 sources · Latest source check 2026-10-09 UTC

On this page

Vitamin K is a family of fat-soluble compounds involved in making clotting proteins and other proteins. K1 is phylloquinone; K2 comprises several menaquinones. A necessary role in clotting or bone metabolism does not establish that every K2 supplement prevents fractures or reverses calcification.[1]

The label covers several compounds

The label covers several compounds
Name	What it describes
K1 / phylloquinone	A major dietary form, particularly in leafy vegetables.[1]
K2 / menaquinones	A family with several side-chain lengths.[1]
MK-4 / MK-7	Different members of that family.[1]

K1 and K2 have different food distributions

NIH describes K1 chiefly in green leafy vegetables and K2 in some fermented and animal foods. Gut bacteria also produce menaquinones, but how much this contributes to an individual’s absorbed supply is uncertain. A bacterial-production claim does not establish that everyone can meet their needs without dietary vitamin K or that one fermented food is required.[1]

Consistency matters with vitamin K antagonists

Warfarin acts against vitamin K’s contribution to clotting. NIH therefore advises consistent vitamin K intake for people taking this class of anticoagulant. This is different from removing all vegetables or independently adjusting a medicine. An anticoagulation plan and a sudden supplement or diet change can interact; the actual drug and clinical monitoring matter.[1]

The intake estimate does not establish a separate K2 requirement

EFSA’s final 2017 opinion could not derive an average requirement or population reference intake and instead used an adequate intake. Although it considered K1 and menaquinones, it set that estimate for phylloquinone because the evidence for menaquinone intake, absorption and function was insufficient. A separate commercial K2 target is not validated by this opinion.[2]

An activation marker and a patient-important outcome are different

EFSA did not find a single biomarker suitable on its own for deriving vitamin K requirements. It also judged the available health-outcome data insufficient for that purpose. A blood value, an undercarboxylated protein measurement, adequate intake and protection against a fracture therefore should not be presented as interchangeable endpoints. The particular claim determines what evidence is needed.[2]

Newborns have a specific preventive-care need

CDC explains that newborns have low vitamin K stores because transfer across the placenta is limited and breast milk contains little vitamin K. Its 2025 FAQ recommends the vitamin K injection at birth as the best way to prevent vitamin K deficiency bleeding, or VKDB. This is prevention for a vulnerable life stage, rather than an adult wellness-supplement protocol.[3]

A healthy appearance cannot reliably identify a baby who is safe to wait

CDC cautions that bleeding may occur inside the intestines or brain before parents recognize a problem. Risk can persist for months in otherwise normally developing infants who did not receive prevention. Waiting for an obvious symptom therefore differs from preventing the deficiency-related bleeding in advance. Birth-care questions belong with the neonatal care team.[3]

Early, classical and late VKDB describe timing

CDC separates early bleeding in the first day, classical bleeding during the first week and late bleeding after that, potentially up to six months. Late VKDB can involve brain bleeding and often lacks warning bleeds. The categories explain when the event presents; they are not separate reasons to assume that a healthy infant needs no prevention.[4]

Serious infant symptoms need prompt medical attention

CDC lists unexplained bruising or bleeding, blood in vomit or stool, excessive sleepiness, seizures and other concerning features. These can require urgent medical assessment and are not symptoms to manage with an adult supplement. Not every symptom is specific to VKDB, and lack of a visible external bleed does not exclude internal bleeding.[4]

Evidence & uncertainty

Evidence differs by purpose. CDC recommends newborn vitamin K prevention against serious bleeding. Adult supplementation claims require separate studies: a trial in older men changed a vitamin-K-related biomarker without showing slower aortic-valve calcification. These findings should not be combined into a general claim that vitamin K is either universally beneficial or ineffective.[3][6]

Selected-source overview · Independent review pending

Published questions

Are vitamin K1 and K2 identical compounds?

Selected-source overview · Independent review pending. Read the evidence context.

K1 is one form; K2 is a family of menaquinones.[1]

Evidence behind this answer

Vitamin K: Health Professional Fact Sheet
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Family of compounds, food sources, bacterial contribution and warfarin consistency